{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-190074","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.166781+00:00","generated_at":"2026-06-13T05:42:05.479906+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eliem halts Kv7 program, explores strategic alternatives including sale or merger","bullets":["Halts further development of Kv7 program; shifts focus to maximizing shareholder value.","Engages Leerink Partners as strategic advisor to explore acquisition, merger, or business combination.","Reports preliminary unaudited cash, cash equivalents, and marketable securities of ~$102.6M as of June 30, 2023.","No timetable set for strategic review; no assurance any transaction will occur."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-190074","json":"https://secwatch.observer/filing/0001193125-23-190074.json","markdown":"https://secwatch.observer/filing/0001193125-23-190074.md","text":"https://secwatch.observer/filing/0001193125-23-190074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312523190074/0001193125-23-190074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312523190074/d485991d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:42:05.479906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}